European Association of Health Law's Interest Group on Supranational Biolaw
Acronym: EAHL IG Supra Biolaw
General Information
Identification Code: 355125643322-26
Website: [object Object]
Entity Form: none
Registration Category: Think tanks and research institutions
Registration Date: 6/26/2021
Last Update: 9/4/2023
EP Accredited Number: 0
Mission & Interests
Goals: The aim of the EAHL Interest Group on Supranational Biolaw is to promote European health law, especially in its European-level dimension. It has three types of activities that correspond to the activities of European Association of Health Law (EAHL). They are conducted specifically regarding the Supranational European dimension of biolaw and thus go beyond comparisons of national biolaws.
1/ Research
- Promote the Supranational European dimension of biolaw;
- Organise scientific events;
- Launch joint research projects on selected topics of common interest to advance legal reflection;
- Achieve international publications.
2/ Training
- Organise training events,
- Facilitate teaching exchanges relating to Supranational Biolaw, and guest lectures and seminars.
- Provide training or events to society at large.
3/ Networking
- Members mobilise their respective networks to promote access of young researchers to positions in Supranational Biolaw, and for visibility
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Public health
- Research and innovation
Levels of Interest:
- european
- national
- global
Activities
Main EU Legislative Proposals: The EAHL Interest Group on Supranational Biolaw in interested in all EU activities related to European Health Law, especially European Biolaw.
Our activities mainly focus on the European Health strategy, including especially the European health Union and the pharmaceutical strategy, but also the research strategy Europe 2020.
The main legislations/policies we are interested in are:
- "Building a European Health Union: Reinforcing the EU’s resilience for cross-border health threats" COM(2020) 724 final
- "Pharmaceutical strategy for Europe" COM(2020) 761 final
- Regulation (EU) 2021/522 establishing a Programme for the Union’s action in the field of health (‘EU4Health Programme’) for the period 2021-2027
- "the Global Approach to Research and Innovation" COM(2021) 252 final
- Directive 2001/83/EC and its amendments
- Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components
- Directive 2004/23/EC on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells
- Directive 2010/45/EU on standards of quality and safety of human organs intended for transplantation
- Directive 2009/41/EC on the contained use of genetically modified micro-organisms
- Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms
- Regulation (EU) 2017/746 on in vitro diagnostic medical devices
- Regulation (EU) 2017/745 on medical devices
- Council Regulation (EU) No 557/2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking
- Regulation (EC) No 1394/2007 on advanced therapy medicinal products
- Regulations (EC) No 1901/2006 and 1902/2006 on medicinal products for paediatric use
- Regulation (EC) No 141/2000 on orphan medicinal products
- Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use
- Directive 2011/62/EU on falsified medicinal products
- Regulation (EU) 2021/2282 on health technology assessment
- Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare
- Directive 98/44/EC on the legal protection of biotechnological inventions
- Regulation (EU) No 1257/2012 implementing enhanced cooperation in the area of the creation of unitary patent protection
- Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data
- Council Directive 89/105/EEC relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems
Communication Activities: Since its launch, the IG has conducted the following activities which cover legal analysis of EU law and policies (Research in law), thanks to the involvement of several of its members.
Members of the group have provided oral communications in several International conferences, and published several articles in the field of EU Health law.
Most importantly, the group has been selected to work on Anti-microbial resistance for WHO in 2021. It has also lead a 2021 Thematic Network under the EU Health Policy Platform on “Health as a fundamental value: Towards an inclusive and equitable pharmaceutical strategy for the EU”. The Joint Statement provided on this topic has been favorably received by DG Health and endorsed by several organizations. The European Commission decided on 9 June 2022 to make this thematic network permanent by transforming it into a stakeholder network. The EAHL IG Biolaw will thus continue to use this platform to promote the debate around an inclusive pharmaceutical strategy.
Full information on the group's activities are available at https://eahl.eu/eahl-interest-group-supranational-biolaw
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Dr Aurélie Mahalatchimy UMR 7318 DICE CERICAix-Marseille Université Espace René Cassin
Post Code: 13628
City: Aix-en-Provence
Country: FRANCE
Phone: [object Object]
EU Office
Address: Dr Aurélie Mahalatchimy UMR 7318 DICE CERICAix-Marseille Université Espace René Cassin
Post Code: 13628
City: Aix-en-Provence
Country: FRANCE
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: L'EAHL IG on Supranational Biolaw n'a pas de fond propre.
Membership Information
Members10 Percent: 0
Members25 Percent: 2
Members50 Percent: 0
Members75 Percent: 0
Members: 2
Members F T E: 0.5
Structure
Structure Type: Structure
Is Member Of: https://eahl.eu/eahl-interest-group-supranational-biolaw
Organisation Members: The EAHL Interest Group on Supranational Biolaw (https://eahl.eu/eahl-interest-group-supranational-biolaw) is part of the European Association of Health Law (https://eahl.eu/). It includes members of the Association who have research interests in Supranational biolaw.